Ginkgo Bioworks Acquires Project Beacon COVID-19 LLC

Ginkgo Bioworks Acquires Patch Biosciences

February 28, 2024

Biotechnology

Ginkgo Bioworks has acquired Patch Biosciences, a startup that built an AI platform for sequence design to advance genetic medicines. The acquisition will integrate Patch's machine‑learning models and validated assays into Ginkgo's platform to expand its gene therapy, cell therapy and RNA therapeutics capabilities for biopharma customers.

Ginkgo Bioworks Acquires Assets from Bitome

June 6, 2022

Biotechnology

Ginkgo Bioworks acquired certain assets from Bitome, a Boston-based developer of real-time metabolite monitoring technology, to integrate continuous metabolite monitoring into its cell engineering platform. The acquisition is intended to accelerate design-build-test-learn cycles and bioprocess optimization across Ginkgo’s portfolio of cell programs by providing real-time metabolic data and ML-driven insights.

Ginkgo Bioworks to Become Public Company via Business Combination with Soaring Eagle Acquisition Corp

May 11, 2021

AI & Machine Learning

Ginkgo Bioworks agreed to a business combination with special purpose acquisition company Soaring Eagle Acquisition Corp., which would result in Ginkgo becoming a publicly listed company. The transaction is expected to close in the third quarter of 2021 and is expected to provide up to $2.5 billion of gross cash proceeds, including $775 million from a PIPE.

Ginkgo Bioworks Acquires Proof Diagnostics

February 28, 2024

Biotechnology

Ginkgo Bioworks has acquired Proof Diagnostics to integrate Proof's OMEGA nuclease libraries and portable diagnostic technologies into Ginkgo’s gene therapy and genetic medicines platform. The deal expands Ginkgo’s gene editing toolkit and diagnostic capabilities to better serve customers developing programmable medicines and rapid detection systems.

Eurofins Scientific Acquires Beacon Discovery

February 18, 2021

Biotechnology

Eurofins Scientific has agreed to acquire Beacon Discovery, a San Diego–based drug discovery CRO specializing in GPCR research and compound libraries. The acquisition expands Eurofins Discovery’s integrated drug discovery capabilities, adding GPCR expertise and proprietary compound resources to support pharmaceutical and biotech clients. The transaction is expected to close in the coming weeks subject to customary conditions.

Ginkgo Bioworks to Acquire Zymergen

July 25, 2022

Biotechnology

Ginkgo Bioworks (NYSE: DNA) has entered into a definitive agreement to acquire Zymergen (Nasdaq: ZY) in an all-stock transaction valued at approximately $300 million market capitalization. The deal is expected to close in the first quarter of 2023, pending Zymergen stockholder approval, regulatory approvals, and other customary closing conditions.